Importantly, 1 mo after drug is stopped in our durability treatment, C5a levels were reduced on a cytokine array, suggesting that activation of the C5a pathway is reduced as an anti-tumor environment cytokine/chemokine develops (Fig 6D). The gene discussed is C5AR1; the disease is neoplasm.